Interferon alfa-2b
Intron A, IntronA (interferon alfa-2b) is a protein pharmaceutical. Interferon alfa-2b was first approved as Intron A on 1986-06-04. It is used to treat bcr-abl positive chronic myelogenous leukemia, brain neoplasms, chronic hepatitis b, chronic hepatitis c, and colorectal neoplasms amongst others in the USA. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia, carcinoid tumor, chronic hepatitis b, chronic hepatitis c, and follicular lymphoma amongst others. It is known to target interferon alpha/beta receptor 1 and interferon alpha/beta receptor 2.
| Trade Name | IntronA |
|---|---|
| Common Name | Interferon alfa-2b |
| ChEMBL ID | CHEMBL1201558 |
| Indication | bcr-abl positive chronic myelogenous leukemia, brain neoplasms, carcinoid tumor, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, condylomata acuminata, cryoglobulinemia, essential thrombocythemia, follicular lymphoma, hairy cell leukemia, hemangioma, hepatitis d, hepatocellular carcinoma, herpes genitalis, hypereosinophilic syndrome, ileal neoplasms, kaposi sarcoma, lymphomatoid granulomatosis, macular degeneration, malignant carcinoid syndrome, melanoma, multiple myeloma, mycosis fungoides, polycythemia vera, renal cell carcinoma, sezary syndrome, skin neoplasms, skin ulcer, thrombocytopenia, thrombocytopenic purpura, thyroid neoplasms, warts |
| Drug Class |
